Search

Given the high mortality rate observed in our data, tocilizumab is not recommended as a salvage therapy for patients affected by acute exacerbation of pulmonary fibrosis who did not show clinical improvement after three steroids bolus https://bit.ly/3ClggYb., Competing Interests: Conflict of interest: M. Le Brun reports grants or contracts from GSK and AstraZeneca; payment or honoraria for lectures, presentations, manuscript writing or educational events from GSK, La revue du praticien and AstraZeneca; and support for attending meetings and/or travel from Asten Santé, Novartis and Sanofi; all outside the submitted work. Q. Philippot reports grants or contracts from Fondation Bettencourt Schuller and royalties or licenses form Elsevier, all outside the submitted work. C. Dupin reports consulting fees from AstraZeneca, Sanofi and GSK; lecture honoraria from AstraZeneca, GSK, Sanofi, Novartis, Chiesi, OPA Pratique, Pneumoscoop and La Lettre du Pneumologue; and travel support from AstraZeneca, Sanofi, Novartis, Chiesi and GSK; all outside the submitted work. M-P. Debray reports consulting fees from Boehringer Ingelheim and Sanofi, and support for attending meetings and/or travel form Boehringer Ingelheim, all outside the submitted work. R. Borie reports consulting fees from Boehringer Ingelheim, Ferrer and Sanofi; payment or honoraria for lectures, presentations, manuscript writing or educational events from Boehringer Ingelheim; and support for attending meetings and/or travel form Boehringer Ingelheim, all outside the submitted work. B. Crestani reports grants or contracts from Boehringer Ingelheim; consulting fees from BMS, Boehringer Ingelheim, Chiesi, GSK and Sanofi; payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, BMS, Boehringer Ingelheim, GSK, Novartis, Roche and Sanofi; support for attending meetings and/or travel from AstraZeneca, BMS, Boehringer Ingelheim, Roche and Sanofi; participation on a data safety monitoring board or advisory board for BMS, Boehringer Ingelheim, Horizon and Sanofi; and he is president of the board of the Fondation du Souffle, a French charity, all outside the submitted work. G. Franco, P. Le Guen, C. Bancal and C. Taillé have no conflict of interest to declare., (Copyright ©The authors 2024.)

Articular manifestations should be screened before and during anti-IL-5/5R biologic treatment in severe asthma. Rigorous multidisciplinary team discussion should be carried out to assess the risk-benefit balance of withholding effective treatment. https://bit.ly/3vfPn4k., Competing Interests: Conflict of interest: C. Dupin reports consulting fees from AstraZeneca, Sanofi and GSK; lecture honoraria from AstraZeneca, GSK, Sanofi, Novartis, Chiesi, OPA Pratique, Pneumoscoop and La Lettre du Pneumologue; and travel support from AstraZeneca, Sanofi, Novartis, Chiesi and GSK; all outside the submitted work. Conflict of interest: L. Guilleminault reports grants from AstraZeneca; consulting fees from Bayer, MSD, AstraZeneca, GSK, Novartis, Sanofi and Chiesi; lecture honoraria from MSD, AstraZeneca, GSK, Novartis, Sanofi and Chiesi; payment for expert testimony from Bayer, MSD and Sanofi; and travel support from MSD, AstraZeneca, GSK, Novartis and Sanofi; all outside the submitted work. Conflict of interest: G. Devouassoux reports lecture or consulting fees from GSK, Menarini, ALK, AstraZeneca, Novartis, Chiesi and Sanofi; payment for expert testimony from GSK, AstraZeneca, Sanofi and Chiesi; and travel support from AstraZeneca, GSK, Sanofi, Novartis, Chiesi; all outside the submitted work. Conflict of interest: M. Le Brun reports grants from GSK, AstenSante and Novartis; lecture honoraria from GSK and La Revue du Praticien; and travel support from Asten Santé and Novartis; all outside the submitted work. Conflict of interest: G. Mourin reports lecture honoraria from AstraZeneca and GSK; and travel support from AstraZeneca, Sanofi, Menarini and GSK; all outside the submitted work. Conflict of interest: P. Bonniaud reports grants from AstraZeneca; lecture honoraria from Sanofi and AstraZeneca; travel support from AstraZeneca, Novartis and Sanofi; advisory board participation from AstraZeneca, Novartis, Sanofi and GSK; all outside the submitted work. Conflict of interest: E. Ebstein reports consulting fees from Abbvie, Novartis and BMS; lecture honoraria from UCB and Galapagos; and travel support from UCB and Novartis; all outside the submitted work. Conflict of interest: C. Taillé reports grants from GSK; consulting fees from AstraZeneca, GSK and Sanofi; lecture honoraria from AstraZeneca, GSK, Sanofi, Novartis, Stallergenes and Chiesi; and travel support from AstraZeneca and GSK; all outside the submitted work. Conflict of interest: S. Valéry, M. Merveilleau, M. Russier, J. Pradelli, P-A. Juge all have nothing to disclose., (Copyright ©The authors 2024.)